Ariad Pharmaceuticals (NASDAQ:ARIA) has had a rough year, with the stock down over 60% on a variety of bad news for its primary drug Iclusig. More specifically, past issues with blood clots resulted in the drug being pulled from the market and then returned with stronger warnings about side effects.
Many investors remain committed to Ariad and Iclusig's strong efficacy, even with those safety issues now well known.
In the video below, from Where The Money Is health care analyst David Williamson lays out their argument for Ariad -- and health care analyst Michael Douglass counters with the bear argument and why investing in Ariad may be a mistake.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Things to Watch in the Stock Market This Week
Look for Netflix, P&G, and Starbucks to make big moves over the next few trading days.
E-Commerce Stocks Crushed It in 2017. Will 2018 Be a Repeat?
Here's why the rally among online retailers could continue to reward investors this year.
2U Inc.'s Biggest Growth Opportunities
The company is reaching out to those looking to learn.